跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LENALIDOMIDA STRAGEN 2,5 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
LENALIDOMIDA STRAGEN 2,5 MG CAPSULAS DURAS EFG
Approved
STANDARD
LENALIDOMIDA STRAGEN 2,5 MG CAPSULAS DURAS EFG
Stragen France
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jul 6, 2021
Approval ID
93272e54a5e48f4b
Company
Stragen France
Type
Standard
Approval Details
Approval Id
93272e54a5e48f4b
Drug Cima Aemps Name
LENALIDOMIDA STRAGEN 2,5 MG CAPSULAS DURAS EFG
Register Number
86067
Holder Company Name
Stragen France
Marketing Company Name
Stragen France
Holder Company Detail Path
/organization/stragen-france
Marketing Company Detail Path
/organization/stragen-france
Authorization Date
2021-07-06
Dosage Form
CÁPSULA DURA
Dose
2,5 mg
Route Of Administration
VÍA ORAL
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Stragen France
Company Detail Path
/organization/stragen-france
Company Information
Pharmaceutical Company Name
STRAGEN-FRANCE
Country Name
France
City Name
lyon,auvergne rhone alpes,country_fr
Address
30 RUE EDOUARD NIEUPORT
Active Ingredients
LENALIDOMIDA
2.5 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jul 6, 2021
Approval ID
93272e54a5e48f4b
Type
Standard
Back to CIMA-AEMPS Approvals
